SOX13 and familial pancreatic carcinoma: In order to develop new treatment approaches for pancreatic cancer, the therapeutic value of targeting SOX13 to reduce pancreatic cancer invasion should be further validated by independent cohorts and prospective trials using key agents such as crizotinib previously shown to block key SOX13-related pathways [34] and additional exploration of the regulatory network of SOX13 to elucidate additional molecular targeted agents for SOX13-overexpressing PDAC patients.